immun-ops2020

The MEK effect on cancer — a slow and steady approach to drug resistance

Atebimetinib Combination Shows Promising Survival Data in Pancreatic Cancer

Atebimetinib Plus Chemo Displays Potential Survival Benefit in First-Line Pancreatic Cancer

Immuneering sees 94% survival at 6 months in pancreatic cancer, teeing up pivotal trial plans

Atebimetinib Plus SOC Chemo Improves Survival, Responses in Front-Line PDAC

Immuneering touts strong survival in pancreatic cancer trial

Immuneering says MEK pill beats standard of care in first-line pancreatic cancer